Atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||03/07/2019|
|Rapid review completed||19/07/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||30/07/2019|
|Pre-submission consultation with Applicant||07/10/2019|
|Initial submission received from Applicant||09/12/2019|
|Complete submission received from Applicant||13/01/2020|
|Preliminary review sent to Applicant||05/05/2020|
|NCPE assessment re-commenced||29/05/2020|
|Factual accuracy check sent to Applicant||06/08/2020|
|NCPE assessment re-commenced||14/08/2020|
|NCPE assessment completed||01/09/2020|
|NCPE assessment outcome||The NCPE recommends that atezolizumab (Tecentriq®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.